DNDN - Stock Quote for Dendreon Corp

|CustomizeDNDN quote (NASDAQ Exchange)

27.69 +0.49 +1.80%fyi
After Hours: 27.65 -0.04/-0.15% Vol. 29,720
Previous Close	27.20	Bid	27.70
Open	27.39	Bid Size	200
Day's High	27.85	Ask	27.80
Day's Low	27.31	Ask Size	100
Volume	1.28 Mil	52 Week High	30.42
Avg. Daily Vol. (13 wk.)	3.07 Mil	52 Week Low	2.55

DNDN Intraday Chart

5d 1m 3m 1y 3y 5y 10y

Beta	4.26
Dividend & Yield	NA
Earnings/Share	-1.85
Forward P/E	-46.93
Market Cap.	3.21 Bil
P/E	-14.81
Return on Equity	-296.55
Total Shares Out.	115.94 Mil

Quotes delayed 15 min unless otherwise indicated

Last trade (extended hours) 4:24 PM ET Financial data in U.S. dollars

Your latest quotes: CALM, DNDN, DOW, VTSMX, $DWC, PAYX

News about DNDN

Market Report -- In Play (DNDN) 11/20/2009 Briefing.com
Market Report -- In Play (DNDN) 11/20/2009 Briefing.com
Market Report -- In Play (DNDN) 11/19/2009 Briefing.com
Dendreon's Provenge gets FDA review date 11/20/2009 Associated Press
View all DNDN news

Press releases

Dendreon Announces Webcast Presentations at Upcoming Investor Conferences 11 hours ago PR Newswire
Dendreon Receives FDA Acknowledgement of Complete Response 11/20/2009 PR Newswire
View all DNDN news

News from the Web

Cel-Sci's History of Disappearing Drugs: BioBuzz Yesterday At TheStreet.com
UPDATE 1-FDA says Dendreon's drug application is complete 11/20/2009 At Thomson Reuters
This Is Why You're Not Making Money in the Market 11/17/2009 At Motley Fool
Buzz of the Street: Gold 1100? 11/6/2009 At Minyanville
View all DNDN news

Videos about DNDN

Dendreon Files for FDA Approval of Provenge

Dendreon has completed its FDA submission for prostate cancer drug Provenge, reports CNBC's Mike Huckman.

more...

From Our Sponsors

Stock ratings

	Community Stock Ratings
	CAPS Rating:

1411 users rated this stock

1	Rating: 1 out of 10 Read full report How StockScouter works

Analyst recommendation

Recommendation: Moderate Buy

View analyst ratings

More information for DNDN

Financial highlights

Sales*	108,000.00
Income*	-196.49 Mil
Sales Growth*	-85.10%
Income Growth*	-70.10%
Net Profit Margin	NA
Debt/Equity Ratio	0.58

* last 12 months

More financial information

Funds that own DNDN

Fund Name	% Own
Fidelity Growth Company Fund	7.5
Vanguard Capital Opportunity Fund	2.5
Fidelity OTC Portfolio	1.3
View all funds

Market update 3:32pm ET

7 things to ask before buying a stock

Putting your money in the market can leave you open to some nasty surprises. Avoid them by doing the right research.

More market news

Market Talk With Jim Jubak message board

Go to the Market Talk With Jim Jubak message board

Data providers
Free Real-Time quotes provided by BATS Exchange, Inc.
Analyst Recommendations data provided by Zacks.com.
Quotes supplied by Interactive Data Real-Time Services.
StockScouter data provided by Gradient Analytics, Inc.

Page generated 6:32 PM Eastern Time